Atezolizumab-induced anaphylactic shock in a patient with hepatocellular carcinoma undergoing immunotherapy: A case report

BACKGROUND: Atezolizumab is a programmed death ligand 1 (PD-L1) inhibitor, and its combination with bevacizumab has been proven an effective immunotherapy for unresectable hepatocellular carcinoma (HCC). Treatment with immune checkpoint inhibitors (ICIs) can lead to hypersensitivity reactions; howev...

Descripción completa

Detalles Bibliográficos
Autores principales: Bian, Li-Fang, Zheng, Chao, Shi, Xiao-Lan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8180205/
https://www.ncbi.nlm.nih.gov/pubmed/34141773
http://dx.doi.org/10.12998/wjcc.v9.i16.4110

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8180205/
https://www.ncbi.nlm.nih.gov/pubmed/34141773
http://dx.doi.org/10.12998/wjcc.v9.i16.4110

Ejemplares similares